Answers are grounded in this paper and cite their sources.
Human papillomavirus (HPV) is a predominant etiological factor for cervical cancer globally. However, current vaccines offer type-specific protection restricted to certain genotypes. The L1 capsid protein induces strong type-specific antibodies, whereas the L2 protein contains conserved epitopes capable of eliciting cross-type immune responses. The integration of both proteins into a chimeric antigen offers a promising approach for broader protection. Notwithstanding widespread use of nucleoside-modified mRNA, current findings indicate that unmodified mRNA can still yield efficient protein expression under optimized conditions. This study aimed to produce and validate an in vitro transcribed (IVT) unmodified mRNA encoding a chimeric HPV L1/L2 protein as a proof-of-concept for mRNA-based HPV vaccine development. For in vitro transcription, a linearized plasmid containing a codon-optimized chimeric L1/L2 gene with a complete mRNA expression cassette was used. This plasmid was subjected to in vitro transcription using a T7-driven RNA polymerase enzyme, followed by enzymatic capping to generate a Cap-1 structure. Transcription efficiency was optimized across incubation periods of 1–6 h, and transcript integrity was confirmed by agarose gel electrophoresis. The histidine-tagged protein expression in Vero cells was evaluated by SDS-PAGE and ELISA, with the chimeric L1/L2 antigen detected using an anti-histidine primary antibody. IVT reactions yielded transcript concentrations ranging from 107.24 to 780.64 µg/mL (~2.1–15.61 µg), with a purification recovery rate of approximately 62.84% and maximal yield observed at 6 h. Agarose electrophoresis confirmed intact, high-quality transcripts. In vitro expression analysis demonstrated significantly higher OD450 values in IVT mRNA–transfected cells compared with the non-transfected control (P < 0.01). The findings demonstrated that unmodified mRNA is capable of producing functional chimeric proteins in mammalian cells, thereby providing a foundation for broad-spectrum HPV mRNA vaccine development and underscoring the need for further evaluation in preclinical models.
No takes yet. Share an insight, caveat, or question.
Nshimiyimana et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: